MARKET WIRE NEWS

UCB SA (UCBJF) Q2 2025 Earnings Call Transcript

Source: SeekingAlpha

2025-08-01 17:53:53 ET

UCB SA (UCBJF)

Q2 2025 Earnings Conference Call

July 31, 2025, 8:00 AM ET

Company Participants

Antje Witte - Head of Investor Relations

Emmanuel Caeymaex - Executive VP & Chief Commercial Officer

Fiona du Monceau - Executive Vice President of Patient Evidence

Jean-Christophe Tellier - CEO & Executive Director

Sandrine Dufour - Executive VP, CFO & Chief Corporate Development

Conference Call Participants

Charles Pitman - Barclays Bank PLC, Research Division

Charlie Haywood - BofA Securities, Research Division

Emmanuel Douglas Papadakis - Deutsche Bank AG, Research Division

Jacob Mekhael - KBC Securities NV, Research Division

Maxime Stranart - ING Groep N.V., Research Division

Naresh Chouhan - Unidentified Company

Peter Verdult - BNP Paribas Exane, Research Division

Rajan Sharma - Goldman Sachs Group, Inc., Research Division

Sofia Graeff Buhl-Nielsen - Unidentified Company

Stacy Ku - TD Cowen, Research Division

Xian Deng - UBS Investment Bank, Research Division

Presentation

Antje Witte

Good afternoon, good morning, good evening. Welcome to the UCB Half Year 2025 Capital Market Call. My name is Antje, I'm the Head of Investor Relations at UCB.

Before I introduce you to the agenda and hand over to the speakers today, I'd like to make some remarks. This presentation and the following Q&A session are intended for institutional capital market participants. If you're not, please disconnect now. This video conference is being recorded. You can find the presentation in our download center on our website in the Investor Relations section, of course, if you dial in by phone. And this presentation and the following Q&A session are covered by the disclaimer and safe harbor statement as stated on the Slide 2 of the slide deck. Please kindly read and respect this carefully.

With this, I'd like to introduce you to our speakers today, our CEO, Jean-Christophe Tellier; Fiona du Monceau, Head of Patient Evidence; Emmanuel Caeymaex, Chief Commercial Officer; and of course, CFO, Sandrine Dufour. And then we're going to have a Q&A session with our speakers....

Read the full article on Seeking Alpha

For further details see:

UCB SA (UCBJF) Q2 2025 Earnings Call Transcript
UCB SA

NASDAQ: UCBJF

UCBJF Trading

-5.03% G/L:

$284.3501 Last:

6 Volume:

$284.3501 Open:

mwn-alerts Ad 300

UCBJF Latest News

UCBJF Stock Data

$61,019,221,972
189,594,898
N/A
N/A
Biotechnology & Life Sciences
Healthcare
BE

Subscribe to Our Newsletter

Link Market Wire News to Your X Account

Download The Market Wire News App